CytoSorbents Corp. (CTSO) Starts Presentation at 2nd Annual Marcum MicroCap Conference
CytoSorbents is a critical care-focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. CTSO’s purification technology removes toxic substances from blood and other bodily fluids. The company’s flagship product, CytoSorb®, is approved in the European Union as a safe and effective means to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death. For more information visit the company’s Web site at www.cytosorbents.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
